Display options
Cite
Hung YN, Kadziola Z, Brnabic AJ, et al. The epidemiology and burden of Alzheimer's disease in Taiwan utilizing data from the National Health Insurance Research Database. Clinicoecon Outcomes Res. 2016;8:387-95doi: 10.2147/CEOR.S93323.
Hung, Y. N., Kadziola, Z., Brnabic, A. J., Yeh, J. F., Fuh, J. L., Hwang, J. P., & Montgomery, W. (2016). The epidemiology and burden of Alzheimer's disease in Taiwan utilizing data from the National Health Insurance Research Database. ClinicoEconomics and outcomes research : CEOR, 8387-95. https://doi.org/10.2147/CEOR.S93323
Hung, Yen-Ni, et al. "The epidemiology and burden of Alzheimer's disease in Taiwan utilizing data from the National Health Insurance Research Database." ClinicoEconomics and outcomes research : CEOR vol. 8 (2016): 387-95. doi: https://doi.org/10.2147/CEOR.S93323
Hung YN, Kadziola Z, Brnabic AJ, Yeh JF, Fuh JL, Hwang JP, Montgomery W. The epidemiology and burden of Alzheimer's disease in Taiwan utilizing data from the National Health Insurance Research Database. Clinicoecon Outcomes Res. 2016 Aug 02;8:387-95. doi: 10.2147/CEOR.S93323. eCollection 2016. PMID: 27536149; PMCID: PMC4976820.
Copy Download .nbib Format: NLM
Share it on

Clinicoecon Outcomes Res. 2016 Aug 02;8:387-95. doi: 10.2147/CEOR.S93323. eCollection 2016.

The epidemiology and burden of Alzheimer's disease in Taiwan utilizing data from the National Health Insurance Research Database.

ClinicoEconomics and outcomes research : CEOR

Yen-Ni Hung, Zbigniew Kadziola, Alan Jm Brnabic, Ju-Fen Yeh, Jong-Ling Fuh, Jen-Ping Hwang, William Montgomery

Affiliations

  1. School of Gerontology Health Management and Master Program in Long-Term Care, College of Nursing, Taipei Medical University, Taipei, Taiwan, Republic of China.
  2. Real World Analytics, Eli Lilly GmbH, Vienna, Austria.
  3. Real World Analytics, Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia.
  4. Department of Medicine, Eli Lilly and Company, Taiwan, Republic of China.
  5. Department of Neurology, Neurological Institute, Taipei Veterans General Hospital; Faculty of Medicine, School of Medicine, National Yang Ming University.
  6. Department of Psychiatry, Taipei Veterans General Hospital; Division of Psychiatry, School of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China.
  7. Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia.

PMID: 27536149 PMCID: PMC4976820 DOI: 10.2147/CEOR.S93323

Abstract

PURPOSE: The objectives of this study were to estimate the incidence, cumulative incidence, and economic burden of Alzheimer's disease (AD) in Taiwan, using data from the National Health Insurance Research Database (NHIRD).

MATERIALS AND METHODS: This was a retrospective, longitudinal, observational study using data from the Longitudinal Health Insurance Database of the NHIRD. Patients were included in this study if they were 50 years of age or older and their records included a primary or secondary diagnosis of AD. New patients who met inclusion criteria were followed up longitudinally from 2005 to 2010. Costs were calculated for the first year following the diagnosis of AD.

RESULTS: Overall, a higher percentage of women than men were diagnosed with AD (54% vs 46%, respectively). The first AD diagnosis occurred most frequently in the age of 75-84 years. The person-year incidence rate increased from 5.63/1,000 persons (95% CI, 5.32-5.94) in 2005 to 8.17/1,000 persons (95% CI, 7.78-8.57) in 2010. The cumulative incidence rate was 33.54/1,000 persons (95% CI, 32.76-34.33) in 2005-2010. The total mean inflated annual costs per patient in new Taiwan dollars (NT$) in the first year of diagnosis ranged from NT$205,413 (2009) to NT$227,110 (2005), with hospitalization representing the largest component.

CONCLUSION: AD represents a substantial burden in Taiwan, and based on the observed increase in incidence rate over time, it is likely that this burden will continue to increase. The findings reported here are consistent with previous research. The NHIRD contains extensive real-world information that can be used to conduct research, allowing us to expand our understanding of the incidence, prevalence, and burden of disease in Taiwan.

Keywords: Alzheimer’s disease; incidence; medical costs; resource utilization

References

  1. Curr Ther Res Clin Exp. 2009 Feb;70(1):10-8 - PubMed
  2. Nat Rev Neurol. 2011 Mar;7(3):137-52 - PubMed
  3. Int J Psychiatry Med. 2011;41(1):57-69 - PubMed
  4. Psychol Med. 1994 Aug;24(3):763-70 - PubMed
  5. Drug Des Devel Ther. 2013 Dec 06;7:1471-8 - PubMed
  6. J Alzheimers Dis. 2015;43(4):1271-84 - PubMed
  7. Arch Neurol. 2005 Mar;62(3):447-53 - PubMed
  8. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD003476 - PubMed
  9. J Chronic Dis. 1987;40(5):373-83 - PubMed
  10. Psychiatry Clin Neurosci. 2001 Feb;55(1):21-5 - PubMed
  11. Prim Care Companion CNS Disord. 2013;15(4):null - PubMed
  12. Ont Health Technol Assess Ser. 2014 Feb 01;14(1):1-64 - PubMed
  13. Alzheimers Dement. 2007 Jul;3(3):186-91 - PubMed
  14. Dialogues Clin Neurosci. 2009;11(2):111-28 - PubMed
  15. J Am Geriatr Soc. 1995 Feb;43(2):144-9 - PubMed
  16. Neurology. 2013 May 7;80(19):1778-83 - PubMed
  17. Curr Neuropharmacol. 2008 Jun;6(2):117-24 - PubMed
  18. Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):236-42 - PubMed
  19. J Neurol Sci. 1998 Sep 18;160(1):67-75 - PubMed

Publication Types